Table 2 Association between ER in nonneoplastic tissue and breast cancer status, by study site
Site | Controls | Cases | ||||
|---|---|---|---|---|---|---|
Cells staining for ER | N | (%) | N | (%) | Crude OR (95% CI) | Age-adjusted OR (95% CI) |
Both | ||||||
<1% | 66 | (20.7) | 23 | (11.2) | 1.0 | 1.0 |
1–5 | 79 | (24.8) | 27 | (13.1) | 1.0 (0.5–1.9) | 0.9 (0.5–1.7) |
6–10 | 70 | (21.9) | 51 | (24.8) | 2.1 (1.2–3.8) | 1.5 (0.8–2.8) |
11–33 | 54 | (16.9) | 40 | (19.4) | 2.1 (1.1–4.0) | 1.3 (0.7–2.5) |
34–66 | 37 | (11.6) | 34 | (16.5) | 2.6 (1.4–5.1) | 1.4 (0.7–2.8) |
>66 | 13 | (4.1) | 31 | (15.0) | 6.8 (3.1–15.3) | 2.6 (1.1–6.2) |
Toronto | ||||||
<1% | 63 | (31.5) | 21 | (20.8) | 1.0 | 1.0 |
1–5 | 66 | (33.0) | 23 | (22.8) | 1.0 (0.5–2.1) | 0.9 (0.5–2.0) |
6–10 | 43 | (21.5) | 27 | (26.7) | 1.9 (0.9–3.8) | 1.2 (0.6–2.5) |
11–33 | 17 | (8.5) | 17 | (16.8) | 3.0 (1.3–6.9) | 1.4 (0.6–3.6) |
>33 | 11 | (5.5) | 13 | (12.9) | 3.5 (1.4–9.1) | 1.4 (0.5–3.9) |
Kingston | ||||||
≤10% | 43 | (37.6) | 30 | (28.6) | 1.0 | 1.0 |
11–33 | 37 | (31.1) | 23 | (21.9) | 0.9 (0.4–1.8) | 0.9 (0.4–1.7) |
34–66 | 28 | (23.5) | 25 | (23.8) | 1.3 (0.6–2.6) | 1.1 (0.5–2.4) |
>66 | 11 | (9.2) | 27 | (25.7) | 3.5 (1.5–8.2) | 2.7 (1.1–6.6) |